Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT03445949
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT03445949
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT03445949. Randomized; no masking; primary purpose treatment. Start 2018-01-23 (actual); primary completion 2025-06-23 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure
- Acronym
- SAFE-LAAC
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- short postimplantation dual antiplatelet therapy
- Intervention (Drug)
- extended postimplantation dual antiplatelet therapy
- Intervention (Drug)
- long-term treatment with a single antiplatelet agent
- Intervention (Drug)
- 6 months treatment with a single antiplatelet agent
- Lead sponsor
- National Institute of Cardiology, Warsaw, Poland
- Collaborator
- Medical Research Agency, Poland
Record details
- Record id
cardio:ct-nct03445949- Content hash
6261fa35dc7b02bfa59557182fd42191d615fc6dd743bf4a83d53cceff4f0a92